CBD Before and After Surgery: Is It Safe?

Why your surgical team needs to know about CBD

Anesthesia societies recommend asking every surgical patient about cannabis and cannabinoid use. The useful details are the product type, amount, route, frequency and time of last use. That includes CBD gummies, oils, capsules, topical products, vapes, prescription cannabinoids and products that contain THC. “I use CBD sometimes” is less useful than a specific label and schedule.

The anesthesiologist uses this information to plan safe anesthesia and recovery, not to judge the patient. Cannabinoid use may be relevant to alertness and consent, heart and airway responses, airway concerns with inhalation, anesthesia requirements, postoperative nausea, pain control and medication interactions. Evidence is incomplete and products differ substantially, which makes accurate disclosure more important.

Contact the surgeon’s office before the procedure rather than waiting until arrival. You may not meet the anesthesiologist until the day of surgery, and the team may need time to review prescriptions or give hold instructions. Never omit CBD because it was purchased without a prescription or marketed as natural.

If surgery is urgent, tell the emergency and anesthesia teams as soon as possible. Do not delay emergency care in order to wait out CBD or cannabis use. The clinicians will assess urgency, intoxication, airway and cardiovascular status and choose the safest available plan.

When should you stop CBD before surgery?

There is no single evidence-based interval that applies to every CBD product and operation. A blanket instruction to stop all CBD two weeks before surgery is not supported as a universal rule. Likewise, a recommendation developed for recently smoked cannabis should not be presented as though it automatically governs a CBD-only topical or oral product.

The 2023 consensus guidelines from the American Society of Regional Anesthesia and Pain Medicine recommend universal cannabinoid screening. They advise postponing elective surgery when acute intoxication or impaired decision-making is present. They also recommend delaying elective surgery for at least two hours after smoking cannabis because of the short-term cardiovascular risk associated with smoking. That two-hour statement is not a general clearance time for every edible, oil or CBD product.

The American College of Surgeons provides broader patient guidance recommending no cannabis products within 72 hours of general anesthesia. Different organizations can frame conservative advice differently because the evidence base is limited and heterogeneous. Neither statement should override instructions from the professionals who know the procedure, medications and health history.

If the team tells you to hold CBD, ask for the exact last-use date and whether the instruction covers every formulation, including topicals. Do not replace CBD with THC, delta-8 THC, alcohol, an herbal sleep aid or another unreviewed product during the hold period.

CBD, anesthesia and postoperative medicines

It is reasonable to ask whether CBD can interact with anesthesia, but the answer should acknowledge uncertainty. Perioperative research often groups cannabis products together even though THC and CBD have different effects. Product amounts and CBD-to-THC ratios are often unknown. Few studies directly test purified CBD with specific anesthetic agents in surgical patients.

CBD can affect drug-metabolizing enzymes and transporters in laboratory and prescription-drug contexts. FDA consumer guidance warns that CBD can increase or decrease the effects of other medicines and identifies a potential for liver injury. Prescription cannabidiol labeling warns about somnolence and sedation, particularly with other central nervous system depressants. These facts justify a medication review, but they cannot predict a precise outcome from a retail gummy.

After surgery, medicines may include opioids, benzodiazepines, sleep aids, gabapentin or pregabalin, anti-nausea drugs, antibiotics, anticoagulants and over-the-counter pain relievers. Combining products that impair alertness can worsen drowsiness, judgment, balance or breathing risk. The American Society of Anesthesiologists advises discussing cannabis and CBD use because it may influence anesthesia needs, heart or respiratory issues, postoperative medication choices, nausea and possible interactions.

Smoking or vaping adds a separate concern. Airway irritation and coughing can complicate anesthesia and place stress on some incisions during recovery. A CBD vape should not be treated as equivalent to an oral or topical product merely because the front label emphasizes CBD.

Does CBD thin the blood?

Saying that CBD simply “acts as a blood thinner” overstates the evidence. CBD is not a standard anticoagulant prescribed to prevent clots. The clinically important question is whether a cannabinoid product may interact with a patient’s anticoagulant or antiplatelet medicine, alter drug exposure, or add uncertainty in a procedure where bleeding control matters.

Perioperative cannabinoid guidance highlights potential interactions with medicines such as warfarin, direct oral anticoagulants and clopidogrel. Evidence includes pharmacology, case reports and limited clinical data rather than a universal finding that every CBD serving causes excessive surgical bleeding. Risk may also depend on CBD amount, THC, other ingredients, liver function and the specific medicine.

Never stop warfarin, apixaban, rivaroxaban, clopidogrel, aspirin prescribed for a medical reason or another blood-related medicine on the basis of a blog article. Stopping can create a clotting risk, while continuing through some procedures can create a bleeding risk. The surgeon and prescribing clinician need to coordinate the plan.

Report unusual bruising, prolonged bleeding, black stools, vomiting blood or blood in urine promptly. Severe bleeding, fainting or symptoms of stroke require emergency care. These warnings are not proof that CBD caused the symptom; they identify situations where delay is unsafe.

Can CBD help with pain after surgery?

CBD should not be described as a proven postoperative pain treatment. Studies are few, use different procedures and formulations, and produce mixed findings. A randomized trial after ureteroscopy gave 20 milligrams of FDA-approved cannabidiol oil daily for three days. CBD did not improve pain scores, opioid use, urinary symptoms, sleep or activity compared with placebo.

A separate randomized study after arthroscopic rotator cuff repair evaluated a buccally absorbed CBD product as part of a multimodal regimen. Early findings suggested a pain signal, and a later follow-up found no harmful difference in one-year patient-reported outcomes. That procedure-specific research does not establish that an ordinary CBD oil or gummy provides reliable pain control after other operations.

Systematic reviews of cannabinoids for acute postoperative pain have concluded that evidence is insufficient or inconsistent. Cannabinoids studied in this literature are not always CBD-only, and prescription or research formulations cannot be treated as interchangeable with commercial products. A positive result in one operation should not be generalized across dental, abdominal, orthopedic and cardiac recovery.

Pain itself is useful clinical information. New, severe or escalating pain can signal a complication. Masking it with an unapproved product or reducing prescribed care without instruction can delay assessment. Use the surgeon’s multimodal plan, which may include appropriate non-opioid medicines, ice, elevation, movement guidance, wound care and limited opioids when clinically indicated.

If you hope to reduce opioid use, say so before surgery. The team can explain evidence-based opioid-sparing approaches and safe disposal. Do not combine CBD with an opioid in an attempt to reduce the opioid amount on your own; sedation and medication interactions require professional review.

When can you restart CBD after surgery?

Research has not established one safe restart time for all patients. The type of operation, anesthesia, wound, oral-intake status, liver function, bleeding risk, discharge medicines and reason for CBD use can all change the answer. Someone taking an opioid after major surgery faces different considerations from someone using no sedating medication after a minor local procedure.

Ask the team before discharge, and request a written answer when possible. If they want CBD held until an opioid, anticoagulant or antibiotic course ends, clarify which medicine and which date. If they permit a restart, confirm whether the approval applies to the exact product and route. Do not interpret permission for a topical away from the incision as permission for an edible or vape.

Never apply a CBD topical, balm or oil to an incision, dressing or irritated skin unless the surgical team specifically approves it. Product ingredients can irritate tissue or interfere with wound instructions. Keep every product in its original labeled package so clinicians can identify it if a reaction occurs.

After anesthesia, follow restrictions on driving, alcohol, operating equipment and making important decisions. Feeling normal is not the same as having fully recovered judgment or coordination. A cannabinoid product should not be used to override those restrictions.

A preoperative and discharge checklist

A lot-matched lab report can clarify cannabinoid content and contaminant testing, but it cannot clear a product for surgery. Our CBD COA guide can help you collect accurate product information for the clinical conversation.

Mood Wellness publishes this article and sells CBD products. That commercial relationship makes the boundary especially important: no Mood product is being recommended as an anesthetic, anticoagulant substitute, wound treatment or postoperative pain medicine. The surgical team’s plan comes first.

Who should seek individualized advice early?

Anyone taking an anticoagulant, antiplatelet medicine, opioid, benzodiazepine, sleep aid, anticonvulsant or medicine with a narrow therapeutic range should raise the question early. People with liver disease, significant heart or lung disease, a bleeding disorder, prior anesthesia complications, pregnancy or breastfeeding also require individualized medical guidance.

Frequent cannabis users should report frequency honestly. Abrupt interruption of THC-containing cannabis can lead to withdrawal symptoms in some people, while ASA patient guidance notes minimal withdrawal risk from CBD-only products. A team can plan for sleep, irritability, appetite or other symptoms without encouraging use immediately around anesthesia.

Children and adolescents should not receive an adult consumer CBD product around surgery unless their specialist specifically directs it. The same applies to older adults who may be more susceptible to falls, confusion, sedation or interactions. Keep all cannabinoid products secured away from children and pets.

If a product caused intoxication, marked sleepiness, vomiting, chest symptoms or an allergic reaction, tell the team even if symptoms resolved. Elective procedures may be postponed when a patient’s decision-making capacity is impaired. This is a safety decision, not a punishment.

Sources and editorial review